Oncology

Asia Leaders

Ugur Sahin Has Given BioNTech a EUR16.8 Billion Runway. Six Cancer Readouts Must Now Set Its Direction

BioNTech retains EUR16.8 billion in cash and securities as it approaches six late-stage readouts. Ugur Sahin must convert scientific breadth into a focused cancer business.

Asia Leaders

Uğur Şahin Is Preparing to Leave BioNTech. The Oncology Pipeline Must Outlast Its Founder

BioNTech’s Covid success funded an ambitious oncology pipeline. With Uğur Şahin preparing to leave, clinical execution and succession have become inseparable.

Asia Leaders

Uğur Şahin’s US$11.1 Billion Pumitamig Alliance Now Faces the Phase III Arithmetic

Pumitamig has moved from BioNTech’s US$800 million Biotheus acquisition to an alliance worth up to US$11.1 billion. Uğur Şahin must show that encouraging lung-cancer signals survive global Phase III trials and a crowded competitive field.

Asia Leaders

Vasant Narasimhan Is Funding Novartis’s Next Growth Cycle with Debt, Deals and China Capacity

Vasant Narasimhan has committed Novartis to a rapid sequence of acquisitions and Chinese investment while net debt rises. The strategy could rebuild growth across RNA medicine, oncology and radioligand therapy, but execution now matters more than portfolio rhetoric.

Asia Leaders

Noubar Afeyan Oversaw Moderna’s $2.2 Billion Cost Reset. The Cash Runway Is the Board’s Next Test

Noubar Afeyan’s most consequential job in 2026 is chairing Moderna through a costly transition. The board has backed deep savings and a tighter pipeline; its next obligation is to show that lower spending can produce durable medicines before cash declines too far.